Advanced Biliary Tract Carcinoma Clinical Trial
Official title:
A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver Cancer（PLC）or Biliary Tract Carcinoma (BTC)
This an open-label，Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or chemotherapy (FOLFOX4 or GEMOX regimen) in subjects with Advanced PLC.or BTC Participants with advanced PLC who failed or intolerable to prior systemic therapy will be treated with SHR-1210 plus Apatinib; Participants with advanced PLC or BTC who have never received prior systemic therapy will be treated with SHR-1210 plus FOLFOX4 or GEMOX regimen.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05451290 -
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03704480 -
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.
|
Phase 2 | |
| Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04550624 -
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05969860 -
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
|
Phase 2 | |
| Completed |
NCT01828034 -
First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
|
Phase 1/Phase 2 |